Results 101 to 110 of about 180,170 (299)

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Bortezomib in the management of multiple myeloma [PDF]

, 2009
Jacob P Laubach, Constantine S Mitsiades, Teru Hideshima, Robert Schlossman, Dharminder Chauhan, Nikhil Munshi, Irene Ghobrial, Nicole Carreau, Kenneth C Anderson, Paul G RichardsonDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston ...
Teru Hideshima, et al, Jacob P Laubach, Constantine S Mitsiades   +3 more
core  

Discharge Remote Monitoring Systems for Glycemic Management After Hospital Discharge

Chronic Diseases and Translational Medicine, EarlyView.
Heat map of median number of telehealth interactions by subgroup and theme. Major themes identified included intervention after remote monitoring alerts (e.g., “Team reached out to participant and instructed participant to treat hypo.”), insulin dose adjustments (e.g., “Participant reported that prednisone dose is increasing … Called to discuss insulin
Nirali Shah, Camilla Levister, Riana Jumamil, Carol Levy, Margaret Crawford, Christian Hicks, Selassie Ogyaadu, Aslihan Ipek, Abigail Tamru, Madeleine Rouviere, Leah Kaplan, Ying Xu, Harsimran Singh, Daniel Cherñavvsky, Grenye O'Malley   +14 more
wiley   +1 more source

Unlocking the therapeutic potential of selective CDK7 and BRD4 Inhibition against multiple myeloma cell growth

Haematologica
Multiple myeloma (MM) is a plasma cell malignancy considered incurable despite the recent therapeutic advances. Effective targeted therapies are therefore needed.
Yao Yao, Shuhui Deng, Jessica Fong Ng, Mei Yuan, Chandraditya Chakraborty, Vera JoyWeiler, Nikhil Munshi, Mariateresa Fulciniti   +7 more
doaj   +1 more source

Detecting communities when order and direction matter in social network analysis

Canadian Journal of Statistics, EarlyView.
Abstract A novel algorithm combining both node degree and edge betweenness (node degree+edge betweenness) is developed to highlight gradients in connectivity. It identifies communities within complex directed graphs. These are networks that are composed of actors who have ties that originate and end at themselves (self‐loops).
Benjamin Smith, Tyler Pittman, Wei Xu
wiley   +1 more source

A Rare Case of Nonsecretory Multiple Myeloma in Lagos, Nigeria: A Case Report and Literature Review [PDF]

, 2015
Multiple myeloma (MM) is a plasma cell disorder associated with clonal proliferation of plasma cells. Nonsecretory multiple myeloma (NSMM) is a rare variant of MM and accounts for approximately 1% to 5% of all cases.
Uche, E., John-Olabode, S., Odesanya, M., Dosunmu, A., Akinbami, A.   +4 more
core   +1 more source

Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study

Chinese Medical Journal, 2021
Guang-Zhong Yang, Guo-Rong Wang, Yan-Chen Li, Yin Wu, Wen Gao, Wen-Ming Chen, Peng Lyu   +6 more
doaj   +1 more source

Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma

Clinical Pharmacology &Therapeutics, EarlyView.
The minimal anticipated biological effect level (MABEL) approach to first‐in‐human (FIH) dose calculation can lead to long dose‐escalation periods before observing clinical activity. We used a novel ex vivo MABEL approach to calculate the FIH starting dose for forimtamig, a T‐cell bispecific antibody under investigation for the treatment of relapsed ...
Thomas E. Kraft, Estelle Marrer‐Berger, Sara Belli, Helene Haegel, Anneliese Schneider, Anna Maria Giusti, Michael Bscheider, Wolfgang Jacob, Martin Weisser, Laura Blanco, Nicolas Frances, Eva Rossmann, Guido Steiner, Aintzane Zabaleta Azpiroz, Bruno Paiva, Ludovic Martinet, Tanja Fauti   +16 more
wiley   +1 more source

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions [PDF]

, 2018
Agnieszka Blum, Despina Bazou, Peter O’Gorman Department of Hematology, Mater Misericordiae University Hospital, Dublin, UK Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of ...
Bazou D, Blum A, O'Gorman P
core  

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source